Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
The State and Direction of Treatment of HFrEF in Papua New Guinea
Author(s): Leslie Bahn Kawa Added: 4 months ago

Heart Failure

Prevention & Chronic Conditions
HFSA 22: PROVE-HF: Effect of Sacubitril/Valsartan in Patients with Mitral Regurgitation in Heart Failure with Preserved Ejection Fraction
Author(s): James L Januzzi Added: 1 year ago
HFSA 22 - Dr James Januzzi (Massachusetts General Hospital, US) outlines the findings of the PROVE-HF study, a trial which aimed to determine the effect of sacubitril/valsartan therapy on cardiac biomarkers in patients with mitral regurgitation in heart failure with reduced ejection fraction. Questions: 1. What was the ideology behind PROVE-HF? 2. What is the mechanism of action behind… View more

Heart Failure
Lars Lund
Job title: Associate Professor and Senior Consultant
Dr Lund's expertise is in HF big data and registry-based comparative outcomes studies and pragmatic trials. He is active in programs to improve utilisation of existing evidence-based interventions in heart failure with reduced ejection fraction, as well as in novel interventions. Dr Lars Lund is an Editorial Board member ofCardiac Failure Review. View more
Polypill in Heart Failure Survey
Author(s): Raja Ezman Raja Shariff , Khairul Shafiq Ibrahim , Sazzli Kasim Added: 1 week ago

Standards & Guidelines

Heart Failure
Job title: Associate Professor of Medicine
Dr Anjali Owens is anAssociate Professor of Medicine at the Hospital of the University of Pennsylvania, Philadelphia, US. She completed her medical degree and undergraduate degree at Duke University. She completed internship, residency, chief medical residency and fellowships in Heart Failure and Transplantation and in Cardiovascular Medicine at the Hospital of the University of Pennsylvania. … View more
ACC 23 Late-breaker Discussion: The BETTER-CARE HF Trial
Author(s): Harriette Van Spall , Amrita Mukhopadhyay Added: 1 year ago
ACC.23/WCC — Join Late-Breaker host, Dr Harriette Van Spall(McMaster University, CA) and investigator, Dr Amrita Mukhopadhyay(NYU School of Medicine, US) in their engaging discussion on the BETTER CARE-HF trial (NCT05275920). The BETTER CARE-HF trial investigated the effectiveness of two electronic clinical decision support (CDS) tools to support prescribing proven therapies for heart failure… View more

Standards & Guidelines

Heart Failure
View from the Thoraxcenter: AHA 22 Late-breaking Science Preview
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
In this dynamic late-breaking science preview Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcenter, Erasmus MC, Rotterdam, NL) share their take on the most anticipated trials of the AHA Scientific Sessions. What late-breaking trials should we look out for? Which results are likely to impact your practice? What are the considerations and challenges? Trials covered in detail include: 37s:… View more

Standards & Guidelines

Heart Failure
View from the Thoraxcenter: AHA 22 Late-breaking Science Wrap-up
Author(s): Nicolas M Van Mieghem , Joost Daemen Added: 1 year ago
Stay updated on the AHA 22 late-breaking data! In this information packed episode of the View from the Thoraxcenter, hosts Dr Joost Daemen and Prof Nicolas Van Mieghem (Thoraxcenter, Erasmus MC, Rotterdam, NL) analyse the data from 10 late-breaking trials presented at the Scientific Sessions. What are the key take-aways from AHA 22? What are the most promising findings? How should we understand… View more

Standards & Guidelines

Heart Failure
HFA 23: Trientine-HCL for Treatment of HFrEF
Author(s): James L Januzzi , Harriette Van Spall Added: 10 months ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial. Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or… View more

Heart Failure
Author(s): Joost Daemen , Nicolas M Van Mieghem Start date: Nov 15, 2022

Heart Failure

Electrophysiology & Arrhythmia